OncoSurge: A Strategy for Improving Resectability With Curative Intent in Metastatic Colorectal Cancer
- 1 October 2005
- journal article
- gastrointestinal cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (28), 7125-7134
- https://doi.org/10.1200/jco.2005.08.722
Abstract
Purpose Most patients with colorectal liver metastases present to general surgeons and oncologists without a specialist interest in their management. Since treatment strategy is frequently dependent on the response to earlier treatments, our aim was to create a therapeutic decision model identifying appropriate procedure sequences. Methods We used the RAND Corporation/University of California, Los Angeles Appropriateness Method (RAM) assessing strategies of resection, local ablation and chemotherapy. After a comprehensive literature review, an expert panel rated appropriateness of each treatment option for a total of 1,872 ratings decisions in 252 cases. A decision model was constructed, consensus measured and results validated using 48 virtual cases, and 34 real cases with known outcomes. Results Consensus was achieved with overall agreement rates of 93.4 to 99.1%. Absolute resection contraindications included unresectable extrahepatic disease, more than 70% liver involvement, liver failure, and being surgically unfit. Factors not influencing treatment strategy were age, primary tumor stage, timing of metastases detection, past blood transfusion, liver resection type, pre-resection carcinoembryonic antigen (CEA), and previous hepatectomy. Immediate resection was appropriate with adequate radiologically-defined resection margins and no portal adenopathy; other factors included presence of ≤ 4 or > 4 metastases and unilobar or bilobar involvement. Resection was appropriate postchemotherapy, independent of tumor response in the case of ≤ 4 metastases and unilobar liver involvement. Resection was appropriate only for > 4 metastases or bilobar liver involvement, after tumor shrinkage with chemotherapy. When possible, resection was preferred to local ablation. Conclusion The results were incorporated into a decision matrix, creating a computer program (OncoSurge). This model identifies individual patient resectability, recommending optimal treatment strategies. It may also be used for medical education.Keywords
This publication has 38 references indexed in Scilit:
- Hepatic resection for colorectal metastases – a national perspectiveThe Annals of The Royal College of Surgeons of England, 2004
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004
- Can health care quality indicators be transferred between countries?Quality and Safety in Health Care, 2003
- Colorectal cancer — what is standard surgery?European Journal Of Cancer, 2001
- Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] MetastasesAnnals of Surgical Oncology, 2001
- Statistical Approaches in the Development of Clinical Practice Guidelines From Expert PanelsMedical Care, 1999
- Resection of Nonresectable Liver Metastases from Colorectal Cancer After Neoadjuvant ChemotherapyAnnals of Surgery, 1996
- Resection of colorectal liver metastasesWorld Journal of Surgery, 1995
- One hundred patients with hepatic metastases from colorectal cancer treated by resection: Analysis of prognostic determinantsBritish Journal of Surgery, 1991
- A Method for the Detailed Assessment of the Appropriateness of Medical TechnologiesInternational Journal of Technology Assessment in Health Care, 1986